INVEGA TRINZA
Total Payments
$10.9M
Transactions
26,164
Doctors
6,131
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $22,466 | 356 | 273 |
| 2023 | $68,363 | 1,193 | 859 |
| 2022 | $32,042 | 754 | 563 |
| 2021 | $25,112 | 567 | 384 |
| 2020 | $4,508 | 253 | 199 |
| 2019 | $87,072 | 2,018 | 1,073 |
| 2018 | $5.6M | 8,306 | 2,193 |
| 2017 | $5.1M | 12,717 | 3,334 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,166 | 63.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.7M | 1,990 | 25.0% |
| Travel and Lodging | $656,921 | 1,423 | 6.0% |
| Food and Beverage | $500,445 | 21,530 | 4.6% |
| Consulting Fee | $48,613 | 37 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $1,000 | 1 | 0.0% |
| Education | $142.97 | 17 | 0.0% |
Payments by Type
Research
$7.0M
1,166 transactions
General
$3.9M
24,998 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | Janssen Research & Development, LLC | $2.5M | 0 |
| A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate L | Janssen Research & Development, LLC | $2.4M | 0 |
| A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | Janssen Research & Development, LLC | $1.5M | 0 |
| A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic Treatment | Janssen Research & Development, LLC | $336,038 | 0 |
| Clinical and Cognitive Effects of Paliperidone Palmitate vs. Oral Risperidone in First-Episode Schizophrenia | Janssen Research & Development, LLC | $119,888 | 0 |
| A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated | Janssen Research & Development, LLC | $65,462 | 0 |
| A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic | Janssen Research & Development, LLC | $53,142 | 0 |
| Effects of Paliperidone Palmitate vs. Oral Risperidone in First Episode Schizophrenia | Janssen Research & Development, LLC | $12,060 | 0 |
| Tufts New England Medical Center Caregivers of Individuals Diagnosed with Schizophrenia | Janssen Scientific Affairs, LLC | $10,613 | 0 |
| A Double-blind Randomized Active controlled Parallel group Study of Paliperidone Palmitate 6Month Formulation | Janssen Research & Development, LLC | $4,191 | 0 |
Top Doctors Receiving Payments for INVEGA TRINZA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Lou Fink | — | Austin, TX | $7.0M | 1,168 |
| , MD | Psychiatry | Saint Louis, MO | $235,250 | 228 |
| Sanford Herman | Psychiatry | Jamaica, NY | $231,022 | 325 |
| , M.D., PH.D | Psychiatry | San Rafael, CA | $228,289 | 206 |
| , MD | Psychiatry | Pittsburgh, PA | $166,446 | 196 |
| , M.D | Addiction Psychiatry | Syracuse, NY | $157,878 | 213 |
| , MD | Psychiatry | Durham, NC | $151,700 | 158 |
| , M.D | Psychiatry | Irvine, CA | $144,885 | 206 |
| , M.D | Psychiatry | Pensacola, FL | $128,499 | 185 |
| , MD | Psychiatry | Pittsburgh, PA | $126,451 | 163 |
| , M.D | Psychiatry | Stony Brook, NY | $104,285 | 142 |
| , M.D | Psychiatry | Bronx, NY | $101,156 | 95 |
| , M.D | Internal Medicine | Hickory, NC | $97,391 | 110 |
| , MD | Psychiatry | Bullhead City, AZ | $94,195 | 148 |
| , MD | Psychiatry | Johnson City, TN | $90,591 | 110 |
| , M.D | Psychiatry | San Diego, CA | $88,607 | 94 |
| , M.D | Psychiatry | Glen Allen, VA | $84,414 | 88 |
| , MD | Psychiatry | Toledo, OH | $75,476 | 90 |
| , M.D | Psychiatry | Duluth, GA | $72,590 | 121 |
| , M.D | Addiction Medicine | Chicago, IL | $68,690 | 69 |
| , M.D | Psychiatry | Wakefield, RI | $60,267 | 85 |
| , M.D | Psychiatry | Santa Cruz, CA | $58,604 | 78 |
| , M.D | Psychiatry | Costa Mesa, CA | $53,247 | 41 |
| , D.O | Psychiatry | East Saint Louis, IL | $49,301 | 75 |
| , MD | Psychiatry | Columbus, OH | $44,031 | 56 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $10.9M
- Total Doctors 6,131
- Transactions 26,164
About INVEGA TRINZA
INVEGA TRINZA is a drug associated with $10.9M in payments to 6,131 healthcare providers, recorded across 26,164 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $22,466 was paid across 356 transactions to 273 doctors.
The most common payment nature for INVEGA TRINZA is "Unspecified" ($7.0M, 63.9% of total).
INVEGA TRINZA is associated with 10 research studies, including "A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics" ($2.5M).